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Abstract
Background—Microparticles are now recognised as true biological effectors with a role in 
immunopathology through their ability to disseminate functional properties. Diannexin, a 
homodimer of annexin V, binds to PS with a higher affinity and longer blood half-life than the 
monomer, inhibits prothrombinase complex activity thereby diminishing coagulation and 
reperfusion injury mediators and prevent microvesicle-mediated material transfer. Our aim was to 
determine if Diannexin could modulate microparticle production by endothelial cells by 
interacting with the phosphatidylserine exposure occurring during the release of these vesicles.
Results—In this study we showed that fluorescently labelled Diannexin binds to calcimycin-
activated endothelial cells but not to resting cells. After overnight incubation, Diannexin enters 
cells and their released MP carry Diannexin. Some Diannexin seems to be processed via early 
endosomes and later is found in lysosomes. Both unlabelled Diannexin and fluorescent Diannexin 
inhibit MP release from TNF-activated endothelial cells. However, Diannexin treatment does not 
prevent endothelial activation by TNF. In addition, the inhibitory effect of Diannexin on MP 
release could be observed when cells were pre-, concomitantly or post-treated with cytokines. 
Scanning electron microscopy showed differences in the numbers and types of protuberances at 
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congruency between fluorescent Diannexin labelling and surface protuberances as shown by 
correlative microscopy.
Conclusions—Altogether these data suggest that Diannexin can inhibit endothelial vesiculation 
by binding PS present either at the cell surface or at the level of the inner leaflet of the plasma 
membrane.
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BACKGROUND
Vesiculation is the process through which cells release plasma membrane sub-micron 
vesicles, named microparticles (MP). It occurs after an increase of intracellular calcium, 
subsequent loss of phospholipid asymmetry and exposure of negatively charged 
phospholipids such phosphatidylserine (PS) at the outer leaflet of the plasma membrane. 
Vesiculation is found in all eukaryotic cells but has been particularly studied in vascular 
cells. A hallmark of MP is the presence of PS at their surface, which allows their 
identification using its ligand, annexin V(1). MP are produced and can be detected in the 
blood of healthy subjects where they are thought to participate in homeostasis. In 
pathological conditions, the increased production of MP detected in the plasma of patients is 
often associated with disease severity. This is true for cardiovascular diseases,as well as 
inflammatory and infectious conditions(2-4). In the circulation, MP are produced mainly by 
platelets. Increased release of MP of endothelial origin has been associated with various 
inflammatory diseases such as anti-phospholipid syndrome, cerebral malaria or multiple 
sclerosis(5-8). Inhibition of MP production has been demonstrated using various agents 
which interfere with molecules involved in the production process, such as calpeptin which 
inhibits calpain, a calcium-dependent protease (9, 10), pantethine a key regulator of lipid 
metabolism (11) or in the signalling pathways controlling vesiculation such as Rho 
inhibitors (10, 12, 13).
MP cargo both surface and cytosolic molecules from their cell of origin and therefore appear 
as real biological effectors able to disseminate various functional propertiesat a distance 
from their site of formation. Once they have interacted with their target cells, MP trigger 
responses from these cells which include the activation of coagulation pathways, production 
of inflammatory molecules or induction of apoptosis(14, 15). MP can also transfer active 
molecules to their target cells, providing them with a new phenotype(16, 17). MP-mediated 
material transfer can be inhibited by incubation of the MP with high concentrations of 
annexin V, although this does not modulate the binding of MP to the target cells (18).
Diannexin is a recombinant homodimer of human annexin V that binds PS with a higher 
affinity than that of annexin V and displays a longer half-life than its monomer. By shielding 
PS exposed at the surface of activated cells, Diannexin reduced the interaction with 
procoagulant proteins such as fVa (2 × 36 kDa)(19). In a model of liver ischemia-
reperfusion, treatment with Diannexin protected the liver, whether the treatment was 
administered pre- or post-injury. This effect seemed to occur through protection of the 
Combes et al. Page 2













sinusoidal endothelial cells (20) and a decrease in pro-inflammatory cytokines (21). In other 
models of ischemia-reperfusion, Diannexin reduced tubule damage and leukocyte influx, 
and improved renal function (22). It was cardioprotective in rabbits with severe ischemic 
insult (23). In addition, as annexin V could block material transfer between MP and target 
cells, Diannexin was able to block tumour microvesicle-mediated transfer of EGFR to 
endothelial cells (24).
So far, Diannexin appears to be of great importance in vivo, appearing to shade PS at the 
surface of activated cells or PS positive MP. Recently, Teoh and coll. showed in a murine 
model of ischemia reperfusion that MP could be taken up by hepatocytes and trigger 
injury,and that Diannexin could prevent MP formation and associated inflammation (25). 
However, how Diannexin acts on the vesiculation process, i.e., production of MP itself, is 
not known. In order to understand its mechanism of action, we hypothesised that Diannexin 
modulates MP shedding by binding to PS before or after it is translocated at the cell surface 
during vesiculation.
METHODS
Human brain endothelial cells culture
Human brain microvascular endothelial cells, hCMEC/D3, were cultured as previously 
described (13) on collagen-coated multi-well plates for flow cytometry analysis, Labtek II 
chamber slides for fluorescence microscopy studies and glass coverslips for electron 
microscopy work. Cells were grown to confluence in EBM-2 medium complete with 5% 
FCS, ascorbic acid (5 μg/ml, Sigma), hydrocortisone (1.4 μM, Sigma), CDLC (1:100 
dilution, Invitrogen), HEPES (100 mM, Invitrogen) and β-FGF (1 ng/ml, Sigma). 
hCMEC/D3 were used from passage 28 to 40.
Endothelial TNF stimulation and Diannexin treatment
TNF (50 ng/ml, Peprotech) was added overnight to induce MP production and at 10 ng/ml to 
induce upregulation of adhesion molecules as previously described (13).
A stock solution of Diannexin was prepared from lyophilised Diannexin provided by A.C. 
Allison, then diluted extemporaneously in complete culture medium to final concentrations 
of 5, 15 and 45 nM.
Effects of Diannexin on MP release were analysed according to the following treatments (i) 
pre-treatment: cells were incubated with Diannexin (15 nM) for 5 and 2 h prior to addition 
of TNF (50 ng/ml), (ii) concomitant treatment: cells were incubated with Diannexin (15 nM) 
at the same time as TNF (50 ng/ml), (iii) post-treatment: cells were incubated with TNF (50 
ng/ml) for 0.5 and 2 h prior to addition Diannexin (15 nM). In each case, control wells 
received either medium, TNF or Diannexin.
Detection of MP by flow cytometry
MP were quantified in the culture supernatant of hCMEC/D3 cells treated or not with 
Diannexin +/− TNF after labelling with specific endothelial mAbs against endoglin (PE-
CD105, Beckman Coulter) or ICAM-1 (PE-CD54, Beckman Coulter).
Combes et al. Page 3













Analysis of hCMEC/D3 treated with Alexa Fluor 488- Diannexin
Conjugation of Diannexin to Alexa Fluor 488 (AF) was performed according to 
manufacturer instructions (Invitrogen).
hCMEC/D3 were incubated overnight with AF-Diannexin (15 nM), washed with medium to 
remove excess Diannexin and observed by microscopy. Imaging and analysis were 
performed with the Olympus IX71 microscope, 40 × magnification. In parallel, cells were 
cultured on collagen-coated 24 well plates and treated similarly. After the overnight 
incubation, supernatants were collected and cells were detached for flow cytometry analysis.
Labelling of phosphatidylserine exposure after calcimycin activation
hCMEC/D3 were stimulated for 45 min with calcimycin (A23187, 30 μM), then quickly 
washed with complete medium and labelled with AF-Diannexin for 15 min and observed on 
the Olympus IX71 microscope, 40 × magnification.
hCMEC/D3 surface phenotyping by flow cytometry
After treatment with Diannexin +/− TNF, cells were detached via trypsin/EDTA treatment 
then incubated with PE-conjugated anti-CD54 mAb for 20 min and then analysed by flow 
cytometry. Mean fluorescence intensity and percentage of positive cells was recorded.
Intracellular localisation of Diannexin
hCMEC/D3 were incubated with AF-Diannexin (15 nM) at different incubation times (30 
min, to overnight). LysoTracker Red (50 nM, Invitrogen) was used for the labelling of 
lysosomes and was added 30 minutes before washing and analysis in PBS. For early 
endosome labelling, hCMEC/D3 were fixed with 1% (v/v) PFA for 20 min, washed once in 
PBS, permeabilized with ice cold methanol for 3 min and then rinsed gently twice in PBS. 
Early endosome antigen 1 (EEA-1) was detected using a mouse monoclonal IgG1 to EEA-1 
or Rab 5 revealed with Alexa Fluor 546 conjugated goat anti–mouse secondary antibody 
(1:400, Invitrogen). Both primary and secondary antibodies were diluted in 1% (w/v) BSA 
in PBS and incubated for 30 min at room temperature. Finally, cells were washed in PBS, 
quickly rinsed in water and mounted in Prolong hardening mounting medium (Invitrogen). 
Samples were analyzed by fluorescence microscopy on the IX71 inverted Olympus 
microscope.
Scanning electron microscopy of hCMEC/D3 treated with Diannexin
hCMEC/D3 were pre-treated or not for 2h with Diannexin prior to TNF activation or left 
resting. Cultures were washed in 0.1M sodium cacodylate/0.1M sucrose/pH 7.4 buffer 
solution and fixed in sodium cacodylate buffered 2% (v/v) glutaraldehyde for 30 min. Buffer 
washes were performed prior to post-fixation in 1% osmium tetroxide/0.1M sodium-
Cacodylate for 1 h. Subsequent buffer and water washes were required prior to dehydration 
in 30%, 50%, 70%, 80%, 90% and 99% ethanol, with each step performed twice for 5 min. 
Cells were dehydrated twice in ultrapure ethanol for 10 min each, treated with 
hexamethyldisilazane (HMDS) for 3 min, air-dried briefly and then placed in a desiccator. 
Coverslips were mounted onto SEM specimen stubs with double sided carbon tape, lined 
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with silver dag and platinum coated. Samples were imaged with the Zeiss Ultra Plus by 
secondary electron detection at 10 kV. Coded images were analysed using Image J software. 
Numbers of cells presenting MP at their surface and numbers of MP per cells were counted. 
Statistical analyses were performed between the different groups and then images were 
decoded.
Correlative microscopy
Cells were treated with TNF +/− AF-Diannexin as described above in immunofluorescence 
analysis. Monolayers were scored with a pipette tip and samples were mounted in PBS for 
immediately viewing with the Zeiss LSM 510 Meta confocal microscope. Images were 
collected at 63X oil and the positions of areas of interest were annotated for later use. 
Following viewing, mounting slides were removed and samples were washed with PBS and 
subsequent sodium cacodylate buffer dilutions. Samples were processed for electron 
microscopy as described above. Image processing was performed in Adobe Photoshop with 
the aid of low magnification reference images.
Statistical Analyses
Statistical analyses were performed using Graph Pad Prism 5 software. All data are 
represented as mean ± SD unless otherwise stated.
RESULTS
Diannexin and AF-Diannexin inhibit MP release from TNF-activated hCMEC/D3
Effect of Diannexin on release of CD105-positive MP—To analyse the effect of 
Diannexin treatment on MP release, supernatants of hCMEC/D3 pre-treated for 2 h ± 
Diannexin at 5, 15 and 45 nM were collected after overnight incubation with or without TNF 
(50 ng/ml). MP present in the supernatant were labelled with an anti-CD105 mAb and then 
counted by flow cytometry. A 2.5-fold increase was observed after stimulation with TNF 
(Fig. 1A, p<0.0001). While no difference was observed between the numbers of MP 
collected from resting cells treated or not with Diannexin, a significant decrease in the 
numbers of TNF-stimulated MP was observed in the presence of Diannexin. Interestingly, 
for all doses of Diannexin, a significant fold-increase in MP release could still be observed 
in the supernatants of cells that had received Diannexin + TNF stimulation compared to 
Diannexin alone.
Effect of Diannexin on release of ICAM-1 positive MP—To substantiatethis 
inhibitory effect, we detected MP in the various supernatants after labelling with another 
surface probe (Fig. 1B). MP collected in the conditions described above were labelled for 
ICAM-1 usinga PE-labelled anti-CD54 mAb. TNF stimulation induced a dramatic increase 
in MP release, due to both an increase in numbers of MP and upregulation of the antigen at 
the surface of the mother cells by the cytokine. Treatment with Diannexin at 45 nM did 
significantly reduce the numbers of TNF-induced MP.
Effect of AF-Diannexin on release of CD105-positive MP—As fluorescently 
labelled Diannexin (AF-Diannexin) will be used in further experiments, we assessed the 
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effect of Diannexin after conjugation. In an experimental setup similar to that described 
above, AF-Diannexin readily inhibited the TNF-induced vesiculation when cells were 
treated with 15 nM of AF-Diannexin. No effect was observed at 5 nM and a trend to 
decrease was seen at 45 nM (Fig. 1C).
Effect of pre-, concomitant or post-treatment with Diannexin on MP release
Cells were treated with Diannexin either before (pre-), at the same time (concomitant) or 
after (post-) TNF addition. As controls, cells were left either untreated, treated with TNF or 
with Diannexin alone.
Diannexin pre-TNF treatment—a significant increase in MP numbers was seen upon 
TNF only stimulation, as expected (Fig. 2A, p < 0.005). When cells were treated with 
Diannexin5 h or 2 h prior to TNF, a significant increase in MP release could still be observed 
compared to cells treated with Diannexin alone vs Diannexin/TNF (p < 0.005 vs p < 0.05, 
respectively). However, the TNF-induced MP release was significantly reduced when cells 
treated with Diannexin 2h prior TNF activation compared to cells treated with TNF only 
(Fig. 2A, p < 0.05). When cells were pre-treated with Diannexin for 2 and 5 h, then washed 
prior to TNF activation, no effect on MP release could be observed.
Diannexin/TNF concomitant treatment—When cells were treated with Diannexin and 
TNF simultaneously, they produced significantly fewer MP than cells stimulated by TNF 
only, but still more than resting conditions (Fig. 2B, p < 0.005).
Diannexin post-TNF treatment—When cell were treated with Diannexin 0.5 h and 2 h 
post TNF activation (50ng/ml), a significant increase in MP release was still observed when 
compared with Diannexin +/− TNF (Fig. 2C, p <0.05 and p<0.005, respectively). However, 
the increment in MP release in TNF/Diannexin treated cells was significantly lower than that 
seen with TNF alone (p<0.005, p<0.05, respectively).
AF-Diannexin enters cells after overnight incubation and released MP are labelled
Diannexin has been described to label PS at the surface of red blood cells. To visualise this 
binding to the endothelial cell membrane, Diannexin was labelled with Alexafluor 488 (AF-
Diannexin). As shown in Fig.1Asuppl., after 20 min incubation with AF-Diannexin, the 
resting endothelial monolayer showed no AF-Diannexin staining while cells activated with 
calcimycin (A23187) showed a membrane staining pattern, especially on cells that have 
started to round up, confirming that AF-Diannexin specifically binds to exposed PS. As a 
control, cells were also labelled with FITC-annexin V and a similar pattern was observed, 
albeit with a lower fluorescence intensity (Fig. 1Bsuppl.). This is to be expected, as annexin 
V is FITC-but not AF-labelled and as Diannexin is known to have a higher affinity for PS 
than annexin V monomers.
To evaluate whether the effect of Diannexin on hCMEC/D3 vesiculation is due to an 
inhibition of the activation status of the cells, surface expression of ICAM-1 was assessed by 
flow cytometry (Fig. 1C suppl.). Cells were pre-treated with AF-Diannexin 2 h prior to TNF 
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stimulation (10ng/ml). After an overnight incubation, a similar degree of ICAM-1 up-
regulation was observed at the surface of the cells.
Although AF-Diannexin does not bind to resting cells at the time the surface staining can be 
observed on activated cells (Fig. 1. suppl.), when AF-Diannexin was left in the medium 
overnight, the whole cell population appeared labelled, as determined by both flow 
cytometry and fluorescence microscopy (Fig. 3A left and 3B, respectively). Microscopy 
showed fluorescent staining localised in the peri-nuclear region of the cells (Fig. 3B, insert). 
When the cell culture supernatant was collected, flow cytometry detected AF-labelled events 
that are compatible with MP, in both forward and side scatter (Fig. 3A, right panels). In 
addition, when the supernatant was labelled with an antibody against the endothelial MP 
surface marker CD105, we observed that most of AF positive events were positive for 
CD105, confirming that these are MP from endothelial origin (Fig. 3C).
Intracellular localisation of Diannexin
To determine the intracellular localisation of AF-Diannexin, the kinetics of uptake was 
analysed in parallel with the staining pattern of specific markers for early endosomes 
(EEA1, rab 5, 7 and 11) and lysosomes (lysotracker). As expected,very little staining was 
observed in cells incubated with AF-Diannexin for 15 and 30 min (Fig.4A). A more marked 
perinuclear staining was observed from 45 min onwards with a maximum after overnight 
incubation. At 15 min, very rare AF events colocalised with EEA1 staining (white arrow), 
however, taking into account the weak AF-Diannex in staining, around 30% of AF-
Diannexin co-localised with EEA-1. This was no longer observed at later time points. 
However, when the endosome marker rab 5 was assessed, it appeared as very fine dots 
(compared to the vesicular aspect of EEA1) and could be seen sitting directly beside the AF-
Diannexin, but no co-localisation could be observed after a 60 min incubation (Fig. 4A, right 
panels, red circles to delineate AF-Diannexin labelling in regards to rab5 staining). When 
AF-Diannexin was left overnight it appeared to mostly co-localise with lysotracker, 
suggesting a processing of the molecule via the lysosome pathway. No co-localisation was 
observed with rab-7 and rab-11.
Diannexin treatment affects the cell surface morphology
We have previously shown that increased numbers of cell surface protuberances were 
associated with an increased number of MP present in the culture supernatant, suggesting 
that these protuberances are indeed budding MP (13). These protuberances were enumerated 
at the surface of the hCMEC/D3 irrespective of their size or electro-lucence. Between 7 and 
9 images at x1750 magnification were counted using Image J software. Significantly more 
peri-nuclear protuberances were observed at the surface of TNF-stimulated cells compared 
to resting cells (Fig. 5A). Treatment of resting cells with Diannexin was associated with a 
higher number of protuberances at the cell surface and TNF+Diannexin stimulation still 
induced the release of a higher number of MP compared to resting conditions.
However when the fine morphology of the cell surface was analysed in all experimental 
conditions, we could observe and counted the different types of protuberances were present 
(Fig. 5B). Electro-lucent protuberances (Fig. 5B, left, open arrow) were predominantly 
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observed on TNF-stimulated cells (60%) while protuberances that seemed “upheld’ under 
the surface (Fig. 5B, centre, black arrow) were observed in higher numbers on cells treated 
with Diannexin, either resting or TNF-stimulated (35%and 30%, respectively). Cells without 
protuberances were mainly found in resting conditions (60%, Fig. 5B, right).
Absence of congruency between AF-Diannexin labelling and surface protuberances
To evaluate whether the presence of these peri-nuclear protuberances(13) was related to 
internalised Diannexin, we performed correlative microscopy on cells treated with AF-
Diannexin. When overlaying AF-Diannexin intracellular labelling and SEM of budding 
vesicles, no co-localisation could be observed, suggesting that no electro-lucent 
protuberance is formed where AF-Diannexin is localised (Fig. 6A).
In addition, orthogonal projections of z-stacks showed that some AF-Diannexin appeared to 
be still at the plasma membrane while some was localised below the plasma membrane, as 
seen when imaging γ-cytoplasmic actin that forms an apical sub-membranous meshwork in 
these cells (Fig. 6B) (13).
DISCUSSION
The annexin homodimer, because of its higher affinity to PS than its monomer (26), has 
been originally described as an anti-thrombotic agent with cell protective effects in cases of 
ischaemia reperfusion injuries (22)(20, 23), reduced inflammatory cell infiltration and 
inhibition of apoptosis of β-cell in grafts of islet cells (27). Diannexin is also known for its 
ability to shade PS at the surface of cells, and therefore prevent the interactions of this 
phospholipid, successfully inhibiting coagulation and protecting cells after reperfusion 
injuries. Also, Diannexin cloaking the PS at the surface of vesicles was preventing their pro-
angiogenic properties during tumour development (24). More recently, a direct relationship 
between Diannexin and microparticles was shown by Teoh and coll in vivo(25) but the 
mechanisms by which Diannexin is able to do so have not been assessed. This is what we 
attempted to do in this study where in summary we have demonstrated that (i) Diannexin 
treatment of TNF-stimulated endothelial cells significantly inhibits the release of MP, (ii) 
Diannexin does not prevent upregulation of adhesion molecules at the surface of the treated 
cells but by decreasing the number of MP carrying these adhesion molecules will limit their 
interactions, (iii) although Diannexin is rapidly internalised, its effect can still be observed 
after 24 h, at a time when Diannexin can be observed below the cell surface, possibly bound 
to the PS at the inner leaflet of the plasma membrane but is not associated with the surface 
protuberances (iv) the morphology of the cell is altered after treatment with Diannexin: 
fewer protuberances are observed after TNF activation and when protuberances are present 
they appear upheld.
MP have been described by many, including our group, as biological effectors involved in 
disease pathogenesis. However the fine mechanisms associated with MP release are still not 
fully understood. In our study, Diannexin only showed an inhibitory effect on MP released in 
stimulated conditions. This suggests that the mechanism by which Diannexin interferes is 
not associated with the release of MP in resting conditions. MP released under physiological 
conditions have been often described as “protective” or as having a positive functional effect 
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(2, 10). Diannexin demonstrated protective effects in vivo and, recently, treatment with 
Diannexin during inflammatory conditions was associated with a reduction of MP release in 
vivo(20). Therefore, we can hypothesise that treatment with Diannexin will only 
demonstrate its effects in pathogenic conditions and will not alter the production of 
beneficial MP.
In the present study, treatment of TNF-activated endothelial cells with Diannexin did not 
affect the ability of these cells to respond to pro-inflammatory signals, as shown by the up-
regulation of surface adhesion molecules, suggesting that although MP release was 
significantly decreased, cells would still be able to interact with leucocytes. Whether the 
consequences of these interactions would still be present remains to be determined. We have 
also demonstrated that MP released after TNF+Diannexin treatment carry the same 
detectable levels of adhesion molecules, namely ICAM-1, also suggesting that these MP 
could interact with a target cell. However, due to the reduced number of MP released, the net 
amount of ICAM-1 receptors available for interaction with its ligand would be significantly 
lower. Also, when using fluorescently-labelled Diannexin we showed that MP released by 
Diannexin-treated cells were fluorescent, suggesting that Diannexin was present either at the 
surface of the MP or more likely contained within the MP, as we demonstrated that 
Diannexin was quickly internalised by the endothelial cells. After being internalised, 
Diannexin was detected by confocal microscopy below the plasma membrane, as assessed 
by γ-actin labelling, and one can hypothesise that it was bound to the PS present at the inner 
leaflet of the phospholipid bilayer, therefore preventing additional externalisation of PS. 
This was further demonstrated by correlative microscopy that showed no congruency 
between internalised Diannexin and membrane protuberances that are likely to later be shed 
as MP. This suggests that where protuberances were formed, no Diannexin was present to 
prevent the phenomenon. It therefore seems that Diannexin could not only cloak the PS 
present at the surface of the cells but also the one expressed on the inner surface of the 
plasma membrane, thus preventing both further interaction with external PS and exposure of 
those internalised. This was also visualised by electron microscopy, where Diannexin 
treatment of the cells was correlated with a significant increase of “upheld” protuberances 
that was itself associated with a significant decrease of shed MP found in the supernatant of 
cell cultures. The inhibitory effect of Diannexin was observed whether the cells were treated 
with the inhibitor prior, concomitantly with or after TNF stimulation, suggesting that the 
sole presence of the molecule was able to prevent the effect of TNF. This was confirmed by 
the fact that a pre-treatment by Diannexin followed by a wash of the molecule prior to TNF 
stimulation was enough to remove the inhibitory effect.
We have recently shown that treatment of endothelial cells with the Rho-kinase inhibitor 
Y27632 is associated with a decrease in MP production linked to changes in β and γ actin 
isoforms (13). Here, the apical γ-actin was not modified in the presence of Diannexin, 
suggesting that these two inhibitory effects occur via different mechanisms, with Diannexin 
most likely physically preventing exposure of PS and subsequent MP shedding while 
inhibitors such as Y27632 act on the signalling pathway controlling MP release.
As previously mentioned, Diannexin is internalised and can be found associated with early 
endosomes and later with lysosomes, however this association is not 100% and some 
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Diannexin can definitively be detected below the plasma membrane. In addition, cells are 
still fluorescent 24h after being treated with labelled Diannexin, suggesting that not all the 
Diannexin has been processed in the lysosomes. We cannot exclude the possibility that 
Diannexin itself has been lysed and that only the Alexa fluor remains, however the confocal 
images suggest otherwise, with a staining pattern below the plasma membrane compatible 
with Diannexin bound to internal PS.
CONCLUSIONS
In conclusion, Diannexin is a promising molecule that has already proven its efficacy in 
ischaemia reperfusion injuries but has also a potential as an adjunct therapy in inflammatory 
diseases where MP have a potential deleterious effect. Importantly, by not altering the level 
of MP released by resting cells, Diannexin can be envisaged as a treatment that will not have 
the side effects that a molecule affecting physiological levels and properties would possess.
Supplementary Material
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Inhibition of TNF-induced vesiculation by Diannexin. Resting (open symbols) or TNF-
stimulated (plain symbols) brain endothelial cells were treated with increasing doses of 
Diannexin (0, 5, 15, 45 ng/ml) 2h prior to activation. After an overnight, cell culture 
supernatants were collected an MP quantified by flow cytometry using anti-CD105 staining 
(A, C) or anti-CD54 staining (B). Data are expressed as fold increase compared to resting 
condition from 3 independent experiments (*** = P<0.0001, ** = P<0.001, * = P<0.05; 
Kruskal-Wallis test and Dunns post-test for multiple comparisons). A and B show the effects 
of unlabelled Diannexin on MP release. C shows effects of Alexa fluorlabelled Diannexin on 
MP release.
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Kinetics of Diannexin treatment on MP release. Resting or TNF-stimulated brain endothelial 
cells were treated with a single dose of Diannexin (15 ng/ml) at various time points prior 
(A), concomitantly (B) or post-TNF activation (C). After an overnight, cell culture 
supernatants were collected an MP quantified by flow cytometry using anti-CD105 staining. 
Data are expressed as fold increase compared to resting condition from 3 independent 
experiments (*** = P<0.0001, ** = P<0.001, * = P<0.05; Kruskal-Wall is test and Dunns 
post-test for multiple comparisons).
Combes et al. Page 14














Kinetics of interaction of fluorescently labelled Diannexin with endothelial cells and 
subsequent MP release. Resting cells were incubated overnight with AF-Diannexin, culture 
supernatant was collected and cells detached and analysed by flow cytometry. (A) left 
histogram shows 100% of the cells labelled with Diannexin; right cytogram shows that a 
large majority of the events falling in the MP size gate are labelled with AF-Diannexin. (B) 
shows that after incubation with AF-Diannexin all cells are fluorescent showing a 
perinuclear pattern. (C) confirms that the majority of AF-Diannexin positive events in the 
MP gate are effectively MP as they can be double labelled with endothelial marker CD105-
PE.
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Intracellular localisation of Diannexin. Resting cells were labelled with AF-Diannexin 
(green) for 15, 30, 45 and 60 min, fixed and labelled with early endosome markers EEA1 
(red) or Rab5 (white). When indicated nucleus was counterstained with DAPI. Cells were 
also incubated overnight with AF-Diannexin and stained with live lysosome dye lysotracker 
(red) and imaged within 20 min. (A) shows staining for EEA1 at 15, 30, 45 and 60 min and 
Rab 5/DAPI at 60 min only. Arrow indicates co-localisation between EEA1 and AF-
Diannexin at 15 min. Red circles on Rab5 and merge images show the location of AF-
Diannexin with regards to Rab5. (B) shows partial co-localisation of the lysosome marker ad 
AF-Diannexin after overnight incubation.
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Diannexin treatment affects the cell surface morphology. Resting and TNF-stimulated cells 
were treated with Diannexin, fixed and analysed by scanning electron microscopy. (A) 
Numbers of MP were counted at the surface of the cells (10 cells at x1750 magnification 
were counted). (B) Protuberances at the surface of the cells were categorise as lector-lucent 
(left), upheld (middle) or absent (right) and counted. Graph shows percentages of MP 
counted in each category for all experimental conditions.
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Confocal-scanning electron microscopy correlative analysis of Diannexin and surface 
protuberances. Cells were incubated with AF-Diannexin fixed, imaged by confocal 
microscopy. (A) Cells were then prepared for scanning electron microscopy. The same cells 
were then imaged and both micrographs were overlayed. Surface electro-lucent 
protuberances were outlined in red circles while AF-Diannexin staining was outlined in 
white circles. Overlay shows no congruency between the two structures. (B) Cells were then 
labelled for γ-actin that has an apical distribution in these cells. Projections on x/y axes 
show distribution of AF-Diannexin directly below the plasma membrane.
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